What commercial deal were you expecting? HER-Vaxx is IMU's most advanced IP and they've only presented the data for end of Ph2 clinical trial a few months ago. Of course there will be a lot of competitors, the cancer treatment market is massive and IMU have IP in both solid and blood cancer market. Just as now there are multiple treatments for the same cancer diagnosis, this will be the case in the future as not every patient will respond similar to the same treatment which is evident even in the current clinical trial IMU is conducting.
What commercial deal were you expecting? HER-Vaxx is IMU's most...
-
- There are more pages in this discussion • 1,249 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
-0.006(8.82%) |
Mkt cap ! $455.6M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.1¢ | 6.2¢ | $3.774M | 58.30M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 3402693 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.3¢ | 610000 | 3 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |